Merck KGaA collaborates with PARP inhibitor developer
Merck KGaA and Pfizer are ONCY's collaborators and PARP is a small molecule inhibitor that is synergistic with pelareorep.
Small molecule inhibitors of poly [ADP-ribose] polymerase-1 (PARP-1) have been shown to have significant clinical potential and third generation PARP inhibitors (PARPis) are currently being investigated in CRC and breast cancer clinical trials.
In this context, ONCY's pelareorep has shown to sensitize the immune system in microsatelliete stable (MSS) mCRC for immunotherapies like PARP inhibitors which is leading to revolutionary treatment modalities.
September 21, 2022 -
Merck KGaA, Darmstadt, Germany Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor
https://www.biospace.com/article/releases/merck-kgaa-darmstadt-germany-enters-collaboration-and-option-to-license-agreement-with-nerviano-medical-sciences-to-develop-next-generation-parp1-selective-inhibitor/